PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MRNY vs. MRNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between MRNY and MRNA is 0.97, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


-0.50.00.51.01.0

Performance

MRNY vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in YieldMax MRNA Option Income Strategy ETF (MRNY) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-54.69%
-59.08%
MRNY
MRNA

Key characteristics

Sharpe Ratio

MRNY:

-1.24

MRNA:

-0.94

Sortino Ratio

MRNY:

-2.03

MRNA:

-1.49

Omega Ratio

MRNY:

0.72

MRNA:

0.81

Calmar Ratio

MRNY:

-0.84

MRNA:

-0.66

Martin Ratio

MRNY:

-1.39

MRNA:

-1.20

Ulcer Index

MRNY:

46.58%

MRNA:

51.68%

Daily Std Dev

MRNY:

52.40%

MRNA:

66.19%

Max Drawdown

MRNY:

-76.72%

MRNA:

-93.70%

Current Drawdown

MRNY:

-74.78%

MRNA:

-93.04%

Returns By Period

In the year-to-date period, MRNY achieves a -22.98% return, which is significantly lower than MRNA's -18.88% return.


MRNY

YTD

-22.98%

1M

-10.03%

6M

-53.89%

1Y

-64.73%

5Y*

N/A

10Y*

N/A

MRNA

YTD

-18.88%

1M

-6.02%

6M

-58.38%

1Y

-61.49%

5Y*

13.14%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MRNY vs. MRNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRNY
The Risk-Adjusted Performance Rank of MRNY is 00
Overall Rank
The Sharpe Ratio Rank of MRNY is 00
Sharpe Ratio Rank
The Sortino Ratio Rank of MRNY is 00
Sortino Ratio Rank
The Omega Ratio Rank of MRNY is 00
Omega Ratio Rank
The Calmar Ratio Rank of MRNY is 00
Calmar Ratio Rank
The Martin Ratio Rank of MRNY is 11
Martin Ratio Rank

MRNA
The Risk-Adjusted Performance Rank of MRNA is 88
Overall Rank
The Sharpe Ratio Rank of MRNA is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of MRNA is 55
Sortino Ratio Rank
The Omega Ratio Rank of MRNA is 66
Omega Ratio Rank
The Calmar Ratio Rank of MRNA is 1010
Calmar Ratio Rank
The Martin Ratio Rank of MRNA is 1515
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MRNY vs. MRNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for YieldMax MRNA Option Income Strategy ETF (MRNY) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MRNY, currently valued at -1.24, compared to the broader market0.002.004.00-1.24-0.94
The chart of Sortino ratio for MRNY, currently valued at -2.03, compared to the broader market-2.000.002.004.006.008.0010.0012.00-2.03-1.49
The chart of Omega ratio for MRNY, currently valued at 0.72, compared to the broader market0.501.001.502.002.503.000.720.81
The chart of Calmar ratio for MRNY, currently valued at -0.84, compared to the broader market0.005.0010.0015.00-0.84-0.76
The chart of Martin ratio for MRNY, currently valued at -1.39, compared to the broader market0.0020.0040.0060.0080.00100.00-1.39-1.20
MRNY
MRNA

The current MRNY Sharpe Ratio is -1.24, which is lower than the MRNA Sharpe Ratio of -0.94. The chart below compares the historical Sharpe Ratios of MRNY and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.40-1.20-1.00-0.80-0.60-0.40Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26Feb 02Feb 09Feb 16
-1.24
-0.94
MRNY
MRNA

Dividends

MRNY vs. MRNA - Dividend Comparison

MRNY's dividend yield for the trailing twelve months is around 183.58%, while MRNA has not paid dividends to shareholders.


TTM20242023
MRNY
YieldMax MRNA Option Income Strategy ETF
183.58%178.49%1.75%
MRNA
Moderna, Inc.
0.00%0.00%0.00%

Drawdowns

MRNY vs. MRNA - Drawdown Comparison

The maximum MRNY drawdown since its inception was -76.72%, smaller than the maximum MRNA drawdown of -93.70%. Use the drawdown chart below to compare losses from any high point for MRNY and MRNA. For additional features, visit the drawdowns tool.


-80.00%-70.00%-60.00%-50.00%-40.00%SeptemberOctoberNovemberDecember2025February
-74.78%
-79.76%
MRNY
MRNA

Volatility

MRNY vs. MRNA - Volatility Comparison

The current volatility for YieldMax MRNA Option Income Strategy ETF (MRNY) is 20.52%, while Moderna, Inc. (MRNA) has a volatility of 25.12%. This indicates that MRNY experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
20.52%
25.12%
MRNY
MRNA
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab